HR+/HER2- metastatic breast cancer
Clinical trials for HR+/HER2- metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- metastatic breast cancer trials appear
Sign up with your email to follow new studies for HR+/HER2- metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy for breast cancer aims to outsmart drug resistance
Disease control Recruiting nowThis phase 2 trial is testing whether combining two hormone-blocking drugs, elacestrant and exemestane, can help people with a certain type of advanced breast cancer (HR+/HER2-) that has stopped responding to initial treatments. The study uses a special PET scan to select partici…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Phase 2 • Sponsor: European Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New blood test could personalize breast cancer care
Diagnosis Recruiting nowThis study aims to create a blood test (liquid biopsy) that can detect two key genetic mutations, ESR1 and gBRCA, in patients with a common type of metastatic breast cancer (HR+/HER2-). The test would help doctors choose the most effective treatments without needing a tissue biop…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: European Institute of Oncology • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Can a virtual wellness program help women with advanced breast cancer?
Symptom relief Recruiting nowThis study tests a virtual group lifestyle program for women with metastatic breast cancer. The goal is to see if more support helps them stick with healthy habits like diet and exercise. One hundred women will take part, and researchers will track safety and how well they follow…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Could a lower starting dose help older breast cancer patients stick with treatment?
Knowledge-focused Recruiting nowThis study looks at whether starting with a lower dose of CDK4/6 inhibitor pills (palbociclib or ribociclib) and gradually increasing the dose helps older adults (age 65+) with metastatic breast cancer tolerate side effects better and stay on treatment longer. About 500 participa…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Phase 3 • Sponsor: American Society of Clinical Oncology • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC